当前位置: 首页 >> 检索结果
6043. Benefits and Harms of Cranial Electrical Stimulation for Chronic Painful Conditions, Depression, Anxiety, and Insomnia: A Systematic Review.
作者: Paul G Shekelle.;Ian A Cook.;Isomi M Miake-Lye.;Marika Suttorp Booth.;Jessica M Beroes.;Selene Mak.
来源: Ann Intern Med. 2018年168卷6期414-421页
Cranial electrical stimulation (CES) is increasingly popular as a treatment, yet its clinical benefit is unclear.
6045. Opioid Analgesic Use and Risk for Invasive Pneumococcal Diseases: A Nested Case-Control Study.
作者: Andrew D Wiese.;Marie R Griffin.;William Schaffner.;C Michael Stein.;Robert A Greevy.;Edward F Mitchel.;Carlos G Grijalva.
来源: Ann Intern Med. 2018年168卷6期396-404页
Although certain opioid analgesics have immunosuppressive properties and increase the risk for infections in animals, the clinical effects of prescription opioid use on infection risk among humans are unknown.
6049. Cellulitis and Soft Tissue Infections.
Cellulitis and soft tissue infections are a diverse group of diseases that range from uncomplicated cellulitis to necrotizing fasciitis. Management of predisposing conditions is the primary means of prevention. Cellulitis is a clinical diagnosis and thus is made on the basis of history and physical examination. Imaging may be helpful for characterizing purulent soft tissue infections and associated osteomyelitis. Treatment varies according to the type of infection. The foundations of treatment are drainage of purulence and antibiotics, the latter targeted at the infection's most likely cause.
6051. Should This Patient Receive Hormone Therapy for Her Menopausal Symptoms?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
作者: Eileen E Reynolds.;Carol Bates.;Martha Richardson.;Risa B Burns.
来源: Ann Intern Med. 2018年168卷3期203-209页
Hormone therapy (HT) was widely prescribed in the 1980s and 1990s and has been controversial since the initial results of the Women's Health Initiative (WHI) trial in the early 2000s suggested that it increased risk for breast cancer and coronary heart disease and did not prolong life. However, more recent data and reexamination of the WHI results suggest that HT is safe and effective for many women when used around the time of menopause. Two experts debate the 2017 Hormone Therapy Position Statement of The North American Menopause Society, which recommends HT as first-line treatment of vasomotor symptoms, and apply it to the care of Ms. R, a 52-year-old woman with severe hot flashes, sleep disturbance, and irritability.
|